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BACKGROUND: LIM and SH3 protein 1 (LASP-1) is a nucleo-cytoplasmatic signalling protein involved in cell proliferation and migration
and is upregulated in breast cancer in vitro studies have shown that LASP-1 might be regulated by prostate-derived ETS factor
(PDEF), p53 and/or LASP1 gene amplification. This current study analysed the prognostic significance of LASP-1 on overall survival
(OS) in 177 breast cancer patients and addressed the suggested mechanisms of LASP-1-regulation.
METHODS: Nucleo-cytoplasmatic LASP-1-positivity of breast carcinoma samples was correlated with long-term survival,
clinicopathological parameters, Ki67-positivity and PDEF expression. Rate of LASP1 amplification was determined in micro-dissected
primary breast cancer cells using quantitative RT–PCR. Cell-phase dependency of nuclear LASP-1-localisation was studied in
synchronised cells. In addition, LASP-1, PDEF and p53 expression was compared in cell lines of different tumour entities to define
principles for LASP-1-regulation.
RESULTS: We showed that LASP-1 overexpression is not due to LASP1 gene amplification. Moreover, no correlation between
p53-mutations or PDEF-expression and LASP-1-status was observed. However, nuclear LASP-1-localisation in breast carcinomas is
increased during proliferation with peak in G2/M-phase and correlated significantly with Ki67-positivity and poor OS.
CONCLUSION: Our results provide evidence that nuclear LASP-1-positivity may serve as a negative prognostic indicator for long-term
survival of breast cancer patients.
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Breast cancer is expected to account for 26% of all new cancer cases
among women in the western world of which 89% will survive 5
years after diagnosis (Jemal et al, 2007). In spite of the significant
improvements in diagnostic and therapeutic modalities for the
treatment of cancer patients, metastasis still composes the major
cause of mortality being responsible for 60% of breast cancer deaths
(Hanahan and Weinberg, 2000). Metastatic disease remains generally
incurable with a median survival time of only a few years. Regardless
of the increase in its incidence, mortality related to breast cancer is
decreasing because of raised awareness and screening, as well as
multidisciplinary treatment. The introduction of endocrine therapy
and the treatment with trastuzumab (Herceptin) in patients with
HER-2/neu overexpression reduced the rates of recurrence by 50%
and significantly improved survival (Widakowich et al,2 0 0 7 ) .
Nevertheless, breast cancer remains a multi-step process linked to
more than one single molecular alteration. Therefore, elucidating
genes that are overexpressed in breast cancer cells may yield
promising targets for novel therapeutic agents (Mauriac et al,2 0 0 5 ) .
The LIM and SH3 domain protein (LASP-1) was initially
identified from a cDNA library of breast cancer metastases. It
became the first member of a newly defined LIM-protein subfamily
of the nebulin group characterised by the combined presence
of LIM and SH3 domains (Grunewald and Butt, 2008). LASP-1 is
localised within multiple sites of dynamic F-actin assembly such
as focal contacts, lamellipodia and membrane ruffles it binds to the
specific shuttle proteins Zyxin and lipoma preferred partner (LPP)
and is involved in cell migration and proliferation (Schreiber et al,
1998; Chew et al, 2002; Butt et al, 2003; Nakagawa et al, 2006).
Silencing of LASP-1 by RNA-interference in various cancer cell
lines resulted in strong inhibition of proliferation and migration
with cell cycle arrest in G2/M-phase (Grunewald et al, 2006,
2007b).
LIM and SH3 protein 1 mRNA is expressed ubiquitously at low
basal levels in all normal human tissues, but is overexpressed in
metastatic human breast cancer (Grunewald and Butt, 2008) and
ovarian cancer (Grunewald et al, 2007b; Dimova et al, 2009). In a
recent case–control study, LASP-1-expression correlated signifi-
cantly with tumour size and nodal-positivity (Grunewald et al,
2007a). Albeit the protein is predominantly situated at focal
adhesions, nuclear localisation of the protein could be clearly
detected by confocal microscopy and western blots of cytosolic
and nuclear preparations from various breast cancer cell lines
(Grunewald et al, 2007a). These data prompted us to further
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cytosolic LASP-1-localisation in a large well-characterised cohort
of breast cancer patients and to analyse the nuclear LASP-1-
localisation in the different phases of the cell cycle.
In invasive breast cancer cells, LASP-1-expression was signifi-
cantly inversely affected by prostate-derived ETS factor (PDEF), a
transcription factor known to repress a variety of genes that are
possibly involved in oncogenesis, such as the apoptosis regulator
survivin (Ghadersohi et al, 2007) and the pro-invasive protease
uPA (Turner et al, 2008).
Real-time PCR analysis confirmed upregulation of LASP1
mRNA in PDEF-deficient invasive and highly metastatic breast
cancer cells (MBA-MB-231, BT-549), while in the non-invasive
MCF-7 breast cancer cell line, endogenously expressing PDEF, a
reduced LASP-1 protein level was detected (Turner et al, 2008).
In a study conduced with hepatocellular carcinoma (HCC),
LASP-1 was repressed by wild-type p53 at the transcriptional
level (Wang et al, 2009). Functional negative p53 mutations led to
increased LASP-1-expression and to a more aggressive HCC
phenotype (Wang et al, 2009).
In this study, we aimed to determine whether the PDEF level or
mutations of the tumour suppressor p53 represent a general
mechanism of LASP-1 deregulation in human cancer. Thus, we
analysed several tumour cell lines of different entities as well as
breast cancer tissue for LASP-1-expression in correlation to PDEF
protein concentration and p53 status.
As LASP1 gene amplification was reported earlier in one breast
cancer cell line (Tomasetto et al, 1995b) and in 40% of crude
extracts of lymph nodes derived from metastatic breast cancer
(Tomasetto et al, 1995a) and was accounted for the principal cause
of LASP-1 overexpression, we also re-analysed the rate of LASP1
gene amplification in individual micro-dissected primary breast
cancer cells. It is noteworthy that the LASP1 gene maps to a region
(17q12) that is altered in 20–30% of human breast cancers
(Tomasetto et al, 1995a,b) and tumours bearing amplifications
of 17q11-21 are associated with an adverse prognosis because
of increased resistance to chemotherapy and endocrine therapy
(Ross and Fletcher, 1999).
MATERIALS AND METHODS
Tissue samples
The studies were performed with approval of the ethics committee
of the University of Wuerzburg. Paraffin-embedded tissue samples
of surgical biopsies from 177 patients with invasive breast
cancer were obtained from the Department of Pathology of the
University of Wuerzburg. The patients were aged from 32 to 85
(mean 55.3±11.9) years. All carcinomas were mainly collected
from patients that underwent wide excisions.
Grading of malignancy of ductal carcinomas was evaluated
according to the Scarff, Bloom and Richardson criteria as
suggested by Nottingham City Hospital Pathologists (Dalton
et al, 2000). Tumour staging was performed according to para-
meters of the TNM system (Singletary and Connolly, 2006).
Ten paraffin-embedded breast tissue samples from reduction
mammoplasties were used as control tissue to obtain reference
DNA for the evaluation of the quantitative RT–PCR results.
Immunohistochemistry
For immunohistochemical staining procedures tissue sections were
cut from regular paraffin-embedded tissue at 2–3mm. Sections
were placed onto APES (3-amino-propyltriethoxy-silane; Roth,
Karlsruhe, Germany) coated slides, dewaxed twice in xylene for
10min, rehydrated in graded ethanol (two changes in 96%,
one change in 70%, one change with distilled water) and in
TRIS-buffered saline (25mM TRIS/HCl, pH 7.4, 137mM NaCl,
2.7mM KCl) for 1min each. For antigen retrieval, sections were
subjected to heat pretreatment by boiling in 0.01 M of sodium
citrate buffer (pH 6.0) for 5min in a microwave oven (800Ws
–1).
Endogenous peroxidase was blocked by incubation in 3.0%
hydrogen peroxide in methyl alcohol for 5min, washed in PBS
and incubated in Beriglobin (Aventis-Behring GmbH, Marburg,
Germany) 1:10 in PBS at room temperature (RT) for 15min to
prevent unspecified attachments. Slides were then incubated with
the polyclonal anti-LASP-1 antibody (Butt et al, 2003) diluted
1:1000 in antibody diluent (DAKO, Hamburg, Germany) or with
Ki67 antibody (DAKO) diluted 1:100 in antibody diluent at 41C
overnight followed by EnVision/rabbit detection system (DAKO)
for 30min at RT. 3,30-Diaminobenzidine (DAB; DAKO) was used
as chromogen and sections were counterstained in haematoxylin
(Mayers, Sigma, Deisenhofen, Germany), dehydrated through
graded ethanol (in the inverse way as described above) and
embedded in Entelan (Merck, Darmstadt, Germany). The specifi-
city of the LASP-1 antibody is shown in Supplementary Figure 1.
For PDEF staining, slices were incubated in Beriglobin, diluted
1:50 in PBS at RT for 15min before incubation with polyclonal
anti-PDEF antibody (Invitrogen, Karlsruhe, Germany) diluted
1:50 in ‘antibody diluent’ (DAKO) at 41C overnight. After
washing with PBS, the slides were incubated for 15min with
biotinylated secondary antibody followed by 15min incubation
with streptavidin-HRP (both LSAB2 system DAKO). The specifi-
city of the PDEF antibody is shown in Supplementary Figure 2.
Evaluation of immunohistochemical LASP-1 staining
and LASP-1-IRS
After staining procedure, the slides were screened and scored as
previously described (Grunewald et al, 2007a). To assess the role of
LASP-1 in human breast cancer, we examined its expression in 177
breast carcinoma samples from patients selected randomly from
January 1985 to December 2007. Semi-quantitative evaluation
of LASP-1 immunostaining was carried out by defining the
percentage of positive cells and the staining intensity as described
below. For positive controls, breast cancer sections previously
described as highly LASP-1-positive (Grunewald et al, 2006, 2007a)
were used. No staining was observed in negative controls with
omitted primary antibody or with pre-immune serum (data not
shown).
Scoring of cytosolic LASP-1-expression was carried out in
analogy to the scoring of hormone receptor Immune Reactive
Score (IRS) ranging from 0 to 12 according to Remmele et al
(Remmele and Stegner, 1987), which is used routinely in surgical
pathology for the quantification of hormone receptor expression in
mammary carcinoma.
The percentage of LASP-1-postitive stained cells was scored
in five grades (grade 0¼0–19%, grade 1¼20–39%, grade
2¼40–59%, grade 3¼60–79% and grade 4¼80–100% LASP-1-
expressing tumour cells) by examining 10 high-power fields ( 40
magnification) in each tissue sample. In addition, the intensity of
LASP-1-expression by the tumour cells was determined (score
0¼none, score 1¼low, score 2¼moderate, score 3¼strong). The
multiplication of these two grading scores (% LASP-1-positive
tumour cells staining intensity) calculates the immunoreactive
score for LASP-1-expression (LASP-1-IRS). Examples for the very
heterogeneous LASP-1-expression in invasive breast cancer are
given in Figure 1.
For better statistical discrimination, samples scored with
cytosolic LASP-1-IRS o5 were classified as LASP-1-negative,
those with LASP-1-IRS 45 as LASP-1-positive.
Nuclear LASP-1-staining was scored by determining percentage
of positive nuclei regardless of cytosolic LASP-1-expression and
cytosolic staining intensity. Samples were considered as nuclear-
positive when 10% or more cells showed nuclear LASP-1 staining.
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and D.
The immunomarkers c-erbB2 (HER-2/neu), oestrogen receptor
and progesterone receptor assessed in this study had been
previously detected by standard immunohistochemistry and were
drawn from the archival database of the Department of Pathology
of the University of Wuerzburg.
Scoring of Ki67-positivity
Immunohistochemical scoring was performed by counting
10 randomly selected 40  high-power fields containing repre-
sentative sections of tumour and calculated as the percentage of
positively stained cells to total cells by counting at least 1000
malignant cells. Ki67 X10% nuclear staining was required for a
positive classification (Tan et al, 2005).
Statistical analysis
Associations between nuclear or cytosolic LASP-1-localisation
were evaluated by multivariate non-parametric analysis using
Fisher’s exact (F) and Mann–Whitney (M) test. These tests were
conducted using Graph Pad Prism Software for Windows
(GraphPad Software, Inc., La Jolla, CA, USA). Po0.05 were
regarded as statistically significant.
Tissue preparation, micro-dissection, DNA preparation
In all, 64 formalin-fixed paraffin-embedded breast cancer tissue
samples of the patient cohort and 10 control breast tissues were
placed onto PEN-membrane coated slides (polyethylene naphtha-
late; Leica, Wetzlar, Germany) were deparaffinised (two changes of
xylene, two changes of 96% ethanol, one change of 70% ethanol,
one change with distilled water, 1min each). After staining with
haematoxylin for 90s and eosin for 60s, all sections were rinsed
3  with distilled water. The slides were then air-dried at RT and
used for micro-dissection. Incubation and staining times were kept
as short as possible to enhance DNA recovery and proteinase
K digestion (Godfrey et al, 2000; Ehrig et al, 2001).
Laser capture micro-dissection was performed using the
Laser MicroBeam System (Leica LMD 6000; Leica). Tumour tissue
(2.0–2.5mm
2) was captured into the lid of a 0.5ml reaction tube
and digested with 30ml proteinase K digestion buffer (50mM Tris,
pH 8.1; 1mM ethylenediamine tetraacetic acid; 0.5% Tween 20;
3mUml
–1 proteinase K). Subsequently, the tubes were closed in
this inverted position and incubated for 50–60h at 371C.
Undigested debris was removed by centrifugation at 14000g for
5min, and proteinase K was inactivated by incubation at 951C for
10min. The samples can be stored safely for months at  201C
(Lehmann and Kreipe, 2001).
Quantitative RT–PCR
Quantitative analysis of genomic LASP1 DNA was performed by
monitoring the increase in fluorescence of the dye SYBR Green
(SYBR Green Supermix, Bio-Rad, Munich, Germany) using the
iCycler iQ System (Bio-Rad).
Primers were designed to meet specific criteria by using Primer3
software (http://frodo.wi.mit.edu) (Rozen and Skaletsky, 2000) and
were obtained from Operon Biotechnologie GmbH (Cologne,
Germany). The sequences of the primers used for LASP1 DNA
amplification were 50-TGTCTCCTGACTGGTTGCGT-30, and 50-TG
ATCTGGTCCTGGGTCTTC-30. Primers for GAPDH were used as
internal reference gene: 50-ATCAAGAAGGTGGTGAAGCAG-30 and
50-TACTCCTTGGAGGCCATGTG-30.
SYBR Green PCR was performed in optical caps for a 96-well
tray (Bio-Rad) using a 25ml final reaction mixture containing 1ml
of each primer pair (stock 5mM), 1ml of the micro-dissected lysed
tissue sample, 12.5ml iQ SYBR Green (Bio-Rad) and sterile water.
The reaction mixture was preheated at 951C for 5min, followed
by 40 cycles at 951C, 571C and 721C for 30s each.
All amplification curves generated with SYBR Green from
stained tissue showed the typical sigmoid curve. In every run, a
negative control was included to exclude false-positive results.
Melting curve analysis was implemented to ensure the correct PCR
product. Each tissue sample was analysed at least twice for LASP1
and twice for GAPDH.
The relative gene copy number was evaluated on the basis of the
threshold cycles (CT values) of the gene of interest CT(LASP1) and
of the internal reference gene CT(GAPDH).
The CT(GAPDH)/CT(LASP1) ratio in benign control breast
tissues will reflect non-amplified LASP1 conditions. In case of a
Grade 0 Grade 1
Grade 2 Grade 3
Figure 1 Representative images of heterogeneous LASP-1-expression in human invasive breast cancer. Immunohistochemical staining of LASP-1
(DAB, brown, magnification  20). (A) No LASP-1-expression (grade 0). (B) Low LASP-1-expression (grade 1). (C) Medium LASP-1-expression (grade 2).
(D) High LASP-1-expression (grade 3). Arrows in (C) and (D) point to LASP-1-positive nuclei.
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number will decrease while the values for the CT(GAPDH)/
CT(LASP1) ratio will increase. The reference range from 10 micro-
dissected normal breast tissues was determined as 0.9699±0.0743.
Therefore, the expectation interval can be calculated as:
m±2s¼(0.82127850221.118530727) with m (arithmetic mean)
and s (s.d.).
Cell lines and cell culture conditions
Hepatocellular carcinoma cell lines Hep-3B and Hep-G2, breast
cancer cell lines BT-20, MCF-7 and MDA-MB-231, urothelial
cancer cell lines T24 and RT-4, glioblastoma cell lines U251MG,
U138MG and U87MG, medulloblastoma cell lines DAOY and
D283 as well as chorioncarcinoma cell lines JEG-3 and JAR were
obtained from Cell Line Services (Heidelberg, Germany) and
grown in plastic cell culture flasks in a humidified incubator at
371C under 5% CO2 atmosphere in RPMI 1640 medium containing
10% heat-inactivated fetal bovine serum (PAA, Linz, Austria)
and 1% streptomycin/ampicillin (Invitrogen). Cells were cultured
until homogeneous morphology of cells was reached (passage
3–4) because LASP-1 belongs to a group of several differential
expressed proteins that are upregulated after later passages
(Sun et al, 2006).
p53 Mutations
Cell lines with known p53 mutations are listed in the database:
http://p53.free.fr. All mutations result in a non-functional p53
protein: http://p53.iarc.fr.
Cell cycle synchronisation and FACS analysis
BT-20 cells were rendered quiescent (G0) by serum deprivation in
RPMI 1640 with 0.1% FCS for 24h followed by incubation with
medium supplemented with 10% FCS to allow cell cycle re-entry in
G1. To block S-phase transition, cells were incubated in medium
supplemented with 10% FCS and 2mgml
–1 aphidicolin for 24h
(Sigma). To synchronise the culture at G2/M phase, cells in the
S-phase were released in RPMI 1640 medium supplemented with
10% FCS for 12h.
Cell cycle distribution was monitored by propidium iodide
staining and measuring fluorescence in a FACScan 2 (Becton
Dickinson, Heidelberg, Germany). BT-20 cells were harvested by
trypsination and fixed in 70% ethanol (41C) for 1h followed
by incubated in a solution containing 50mgml
–1RNase in PBS for
30min. For staining, 50mgml
–1 propidium iodide was added for
another 30min. Cells were analysed by FACS, and the proportion
in G0/G1, S and G2/M phases was estimated using Modfit cell cycle
analysis programme. Measurements were performed on at least
three independent synchronisation experiments.
Preparation of nuclear and cytosolic cell fractions
Human breast cancer cell lines were harvested at 80% confluence
through trypsination. Isolation of nuclei and cytosol was carried
out using NE-PER nuclear and cytoplasmic extraction Reagents
(Pierce, Bonn, Germany) following the manufacturer’s instruc-
tions. Samples were solved in Laemmli sample buffer at a final
concentration of 1 10
6ml
–1and stored at  201C before western
blot electrophoresis.
Western blot analysis
For western blotting, cells were lysed in Laemmli sample buffer.
Equal amounts of protein, according to cell count, were resolved
by 12% SDS–PAGE. After blotting on nitrocellulose membrane
and blocking with 3% non-fat dry milk in 10mM Tris, pH 7.5,
100mM NaCl, 0.1% (w/v) Tween 20, the membrane was incubated
with the antibody raised against LASP-1 (1:20000) (Butt et al,
2003) or PDEF antibody (1:1000) followed by incubation with
horseradish peroxidase-coupled goat anti-rabbit IgG (Bio-Rad),
diluted 1:5000, and visualised by ECL (Amersham Biosciences,
Freiburg, Germany). Quantification of autoradiography signals
was carried out by densitometry using the ImageJ software (NIH,
Bethesda, MD, USA).
GAPDH (1:1000; Santa Cruz, Heidelberg, Germany) was used as
a specific cytosolic marker to exclude cytoplasmic contamination
of the nuclei preparation. Anti-Lamin AþC antibody (1:50;
Abcam, Cambridge, UK) served as a specific nuclear marker
to exclude nuclear contamination in cytoplasmic cell samples. At
least three independent experiments have been carried out and
representative results are shown.
RESULTS
Overexpression of LASP-1 in breast cancer is not due to
gene amplification
As increasing amounts of contaminating non-malignant cells lead
to a significant decrease in detection sensitivity (Kallioniemi et al,
1994), we used individual micro-dissected breast cancer cells to
examine the LASP1 copy number in DNA samples from 64 patients
with known invasive breast carcinoma selected randomly from
January 2000 to December 2007.
We detected only 1 out of 64 tissue samples (1.5%) with a
CT(GAPDH)/CT(LASP1) ratio higher than the expectation interval,
showing a negligible rate of LASP1 gene amplification. Therefore,
the observed overexpression of the LASP-1 protein in more than
55% of human breast cancers (Grunewald et al, 2007a) is likely due
to reasons distinct from gene amplification.
LASP-1 overexpression neither correlates with PDEF
expression nor with p53 mutations
Commonly, the inner layer of benign ductal luminal epithelial cells
show a high nuclear PDEF staining while in invasive ductal
carcinoma, a weak PDEF staining is detected mainly in the cytosol
(Feldman et al, 2003), (Figure 2). To determine whether the
reported reciprocal effect of PDEF on LASP-1 in non-invasive and
invasive breast cancer cell lines (Turner et al, 2008) is transferable
to breast tumour patient samples, we evaluated 35 primary breast
cancer tissues for PDEF expression; 17 with known high (X8)
LASP-1 IRS and 18 specimens with low (p3) LASP-1-IRS.
In all 35 tested human breast cancer samples, we observed
a comparable cytosolic PDEF localisation without significant
differences in staining intensity. Only two out of the tested
samples showed in parts additional nuclear PDEF staining. No
correlation between the PDEF levels in invasive ductal carcinoma
and high or low LASP-1 expression could be detected.
When examining tumour cell lines of different entities, an
overall PDEF expression is observed that does not correlate per se
with low LASP-1 protein concentration (Figure 3). For example,
while the PDEF levels are similar in all three tested breast cancer
cell lines (MDA-MB-231, BT-20, MCF-7) LASP-1 expression is only
reduced in MCF-7 cells. Analogous differences are also observed
with glioblastoma and chorioncarcinoma cell lines (Figure 3).
To test whether LASP1 is transcriptionally regulated by p53, we
analysed several human cancer cell lines of different tumour
entities with and without known p53 mutations for LASP-1-
expression by western blot. All mutations result in a functionally
inactive tumour suppressor. In summary, the analysis showed no
correlation between high LASP-1-expression and p53 mutations
(Figure 3). For instance, in spite of the total loss of function
because of an additional stop codon in the p53 gene of the
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T24 urothelial cancer cell lines express high levels of LASP-1. In
contrast, the chorioncarcinoma cell line JEG-3 with a p53 mutation
and the breast carcinoma cell line MCF-7-expressing wild-type p53
show low LASP-1-expression.
Nuclear localisation of LASP-1 correlates with poor long-
term survival
In an earlier case–control study, a strong cytoplasmic staining for
LASP-1 was detected in 455% of the invasive tumours, which
correlated significantly with increased tumour size and rate
of nodal-positivity. In addition, we observed a distinct nuclear
LASP-1-localisation pattern that was absent in benign tissue
(Grunewald et al, 2007a).
We therefore performed a retrospective study (January 1985
until December 2007) with samples of 177 archival cases of
confirmed histological diagnosis of invasive breast carcinomas to
evaluate the long-term survival of breast tumour patients in
relation to nuclear and cytoplasmic LASP-1-positivity.
Cytoplasmic LASP-1 protein expression was detected in 95% of
the breast carcinomas; thereof 31% showed an additional nuclear
LASP-1 staining (Figure 1, Table 1). A low cytoplasmic expression
correlated with negative/low nuclear staining and a high cytoplas-
mic LASP-1-expression with high nuclear localisation (Table 1).
The prognostic effect of nuclear and cytosolic LASP-1 staining
was further tested using the Kaplan–Meier survival analysis. There
was a significant correlation (P¼0.025) between patients with
positive nuclear LASP-1 staining and poor overall survival (OS)
(Figure 4A, Table 2) while there was no significant association
between OS and cytoplasmic LASP-1 staining (Figure 4B,
P¼0.404). Surprisingly, a relationship between high positive
nuclear staining and low grading (P¼0.025) was observed,
whereas all other clinical parameters analysed (i.e., nodal status,
oestrogen and progesterone receptor status, recurrence) did not
correlate with nuclear LASP-1-localisation (Table 3).
Figure 2 Immunohistochemical staining of PDEF (DAB, brown, magnification  400) in benign breast tissue (A and B) and invasive ductal breast cancer
samples (C and D) showing a nuclear PDEF staining in normal tissue and a more cytosolic PDEF localisation in tumour cells.
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Figure 3 PDEF and LASP-1 protein expression in various cancer cell lines with (mut) and without (wt) known p53 mutations that lead to functionally
inactive tumour suppressor protein. b-Actin blotting was used as a control for equal protein loading. Cell lines: hepatocellular carcinoma (Hep-G2, Hep-3B),
glioblastoma (U251, U13898, U87), medulloblastoma (DAOY, D238), urothelial carcinoma (T24, RT4), breast cancer (MDA-MB-231, BT-20, MCF-7) and
chorioncarcinoma (JEG-3, JAR). There is neither a correlation between PDEF and LASP-1 expression nor between LASP-1 protein levels and p53 mutations.
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proliferation and augments in G2/M phase
There are two facts regarding LASP-1 that seem to be linked:
(a) the prominent nuclear localisation of LASP-1 in primary breast
cancer (Figure 1) (Grunewald et al, 2007a) and (b) cell cycle arrest
at G2/M accompanied by reduced cell proliferation after knock-
down of LASP-1 in breast carcinoma cell lines (Grunewald et al,
2006). Therefore, it was tempting to speculate that the rate of
nuclear LASP-1-localisation might be cell cycle dependent. To test
this hypothesis, BT-20 cell lysates were subjected to cytoplasmic
and nuclear fractioning. Purity of the fractions was confirmed by
probing western blot membranes for the nucleus marker Lamin
AþB and the cytoplasmic marker GAPDH. Figure 5A shows that
there was virtually no cross-contamination.
In cells with an asynchronous cell cycle, in non-proliferating
G0 phase cells (resting/senescent) and in G1 phase cells
(G1/S-checkpoint), LASP-1 was found primarily within the
cytoplasm (95%) (Figures 5A and B). During proliferation
(S-phase) the nuclear LASP-1 concentration increased up to 10%
and reached a peak at G2/M phase (G2/M) although the overall
LASP-1 protein level did not change (data not shown).
As LPP and Zyxin are known binding partners of LASP-1
(Keicher et al, 2004; Li et al, 2004) and are discussed as possible
shuttle proteins to transfer LASP-1 into the nucleus we also
controlled their distribution during cell cycle phases. Consistently,
like LASP-1, both proteins showed a cell phase-dependent nuclear
increase in G2/M (Figure 5B) without changes in absolute protein
concentration. All cell cycle phases were controlled by flow
cytometry (Figure 5C).
To further validate the influence of nuclear LASP-1 occurence
on cell proliferation, we quantified the number of positive stained
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Figure 4 Outcome of patients with nuclear and cytosolic LASP-1
localisation. Kaplan–Meier plots measuring patients OS in years against
cumulative survival for nuclear (A) and cytosolic (B) LASP-1 staining. The
analysis included patients diagnosed from 1985 to 2007 (n¼177). Nuclear
LASP-1-positivity is associated with poor OS.
Table 1 Analysis of overall survival in relation to LASP-1 staining
intensity
LASP-1
staining
intensity
No. of
patients
Positive
nuclear
LASP-1
staining
No. of
deceased
patients
Overall
survival (%)
Score 0 9 0 (0%) 0 100
Score 1 46 6 (13%) 7 84.8
Score 2 109 46 (42.2%) 27 75.2
Score 3 13 4 (28.5%) 4 69.2
Total 177 56 (31%) 38 89.6
Abbreviation: LASP-1¼LIM and SH3 protein 1.
Table 2 Analysis of overall survival in relation to nuclear LASP-1-
positivity
Nuclear
LASP-1-
positivity
No. of
patients
No. of
deceased
patients
Overall
survival (%)
No 121 21 82.6
Yes 56 17 69.6
Abbreviation: LASP-1¼LIM and SH3 protein 1.
Table 3 Univariate analysis of positive nuclear LASP-1 staining and
clinicopathological parameters
Parameters Positive nuclear LASP-1 staining P-value
Nodal status
N+ (n¼83) 31 (37.3%)
N  (n¼94) 25 (26.6%) 0.2 (F)
Tumour size
Tis (n¼3) 0 (0.0%)
T1 (n¼108) 37 (34.3%)
T2 (n¼51) 15 (29.4%)
T3 (n¼5) 2 (40.0%)
T4 (n¼10) 2 (20.0%) 0.69 (M)
Metastasis
M+ (n¼6) 1 (16.7%)
M  (n¼171) 55 (32.2%) 0.67 (F)
Grading
G1 (n¼7) 4 (57.1%)
G2 (n¼69) 27 (39.1%
G3 (n¼45) 9 (20.0%) 0.03 (M)
Recurrence
Yes (n¼36) 8 (22.2%)
No (n¼87) 27 (31.0%) 0.38 (F)
ER
ER+ (n¼98) 28 (28,6%)
ER  (n¼62) 23 (37.1%) 0.3 (F)
Progesteron receptor
PR+ (n¼86) 22 (25.6%)
PR  (n¼71) 27 (38.0%) 0.13 (F)
HER2/neu
Her+ (n¼27) 6 (33.3%)
Her  (n¼47) 18 (28.1%) 0.77 (F)
Abbreviations: ER¼oestrogen receptor; F¼Fisher’s exact test; LASP-1¼LIM and
SH3 protein 1; M¼Mann–Whitney Test; PR¼progesterone receptor. Statistical
significance is assumed when Po0.05.
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scells for the proliferation marker Ki67 in 30 breast cancer tissue
samples with known high LASP-1 IRSX8 and either nuclear or
cytosolic LASP-1 localisation.
Although only 30.7% of the invasive ductal carcinoma samples
with cytosolic LASP-1 expression are positive for Ki67 staining,
68.7% of the breast cancer tissues with nuclear LASP-1 occurrence
show positive staining for the proliferation marker Ki67 (w
2 test;
P¼0.04).
DISCUSSION
The LASP1 gene was initially identified from a cDNA library of
metastatic axillary lymph nodes (MLN) from human breast cancer
and therefore called MLN50. The gene was mapped to chromo-
somal region 17q11-q21.3, a region known to contain the c-erbB-2
(HER-2/neu) and the BRCA1 oncogene and to be altered in
20–30% of all breast cancers (Tomasetto et al, 1995a,b). Since its
discovery in 1995, several experimental approaches have been
carried out to determine the cause of LASP-1 overexpression and
its regulatory mechanisms. For instance, LASP-1 overexpression
was reported to be due to LASP1 gene amplification detected in
12 out of 98 tested whole breast cancer samples (Bieche et al, 1996)
while Tomasetto et al detected an amplification of LASP1 only in
one (BT-474) out of eight different breast cancer cell lines
(Tomasetto et al, 1995b). Others observed deregulation of normal
LASP-1-expression in relation to changes in PDEF and urokinase-
type plasminogen activator (uPA) concentration or because of loss
of p53 tumour suppressor activity (Turner et al, 2008; Salvi et al,
2009; Wang et al, 2009).
However, in this work, we analysed the expression pattern of
LASP-1 in primary invasive breast cancers using micro-dissected
tissues. Our data clearly show that the LASP1 gene is not amplified
in the vast majority of human breast cancers (only 1 out of
64 cases), suggesting that LASP-1 overexpression is mediated
through transcriptional regulation rather than gene amplification.
In the context of transcriptional regulation, we revealed that
LASP-1 overexpression does not correlate per se with defects in
the tumour suppressor protein p53 transcriptionally repressing
LASP-1 (Wang et al, 2009). Although the data for the regulation of
LASP1 gene expression by p53 are convincing, there are clearly
additional mechanisms involved in LASP-1 protein upregulation
such as transcriptional cofactors and decay rates than just
functional defects in p53.
As for PDEF, we could not confirm an association between
low PDEF protein expression and high LASP-1 levels although
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Figure 5 Cell cycle-dependent nuclear and cytosolic LASP-1 distribution. (A) Western blotting of nuclear (N) and cytosolic (C) proteins levels of LPP,
Zyxin and LASP-1 in BT-20 cells synchronised to G0, G1, S and G2/M phase. Purity of nuclear and cytosolic fractions was controlled by Lamin AþB and
GAPDH western blots, respectively. (B) Percentage of nuclear LPP, Zyxin and LASP-1 protein concentration (expressed as percentage of total cellular LPP,
Zyxin and LASP-1 protein levels, respectively) plotted against cell cycle phases. (C) Flow-cytometric analysis of cell cycle phases (propidium iodide staining of
total DNA).
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sTurner et al showed that re-expression of PDEF in cells with low
PDEF protein expression resulted in reduced LASP-1 levels
(Turner et al, 2008).
However, PDEF mRNA concentration and protein expression in
breast cancer cell lines is discussed controversially. As reported
earlier, PDEF protein detection did not always correspond to PDEF
mRNA levels. Although some studies showed increased PDEF
mRNA (Turcotte et al, 2007) or protein expression in invasive
ductal carcinoma (Sood et al, 2007) others observed reduced
protein expression in breast cancer cells (Feldman et al, 2003;
Doane et al, 2006; Ghadersohi et al, 2007; Turner et al, 2008).
Recently, this discrepancy was explained by the identification of
two microRNAs in human breast tumour samples that directly
repressed PDEF protein expression in spite of the detection of high
PDEF mRNA concentration (Findlay et al, 2008).
In a recent paper by Grunewald et al, LASP-1 was reported to be
highly expressed in invasive breast carcinomas compared with
fibroadenomas. Strong cytoplasmic staining for LASP-1 was found
in 55.4% of the invasive breast tumours (Grunewald et al, 2007a).
In addition to the reported localisation at focal contacts and
lamellipodia, a perinuclear and nuclear distribution of the protein
was observed. These data hint to a potential additional signalling
function of LASP-1 as a shuttle protein thereby transducing growth
signals from the sites of cellular contacts with the ECM into the
nucleus.
In support of this hypothesis, this work shows a cell cycle-
dependent increase of nuclear LASP-1 during the mitotic G2/M
phase in proliferating tumour cells (Figure 5C) while serum-
starved quiescent cells (G0) as well as cells in G1 and S-phase show
only minor levels of the protein in the nucleus. Our observations
are consistent with earlier data showing a specific cell cycle arrest
at G2/M and inhibition of cell proliferation after LASP-1 knock-
down in breast and ovarian cancer cell lines (Grunewald et al,
2006, 2007a,b). In reverse, a high LASP-1 concentration in the
nucleus would show sustained cell proliferation. In fact, we found
that approximately 70% of the patient samples with nuclear
LASP-1 staining were positive for the cell proliferation marker
Ki67 while only 30% of the patients with cytosolic LASP-1
expression showed positive Ki67 staining.
Consistently, earlier studies revealed a correlation between
LASP-1-expression and tumour size as well as nodal-positivity in
human breast carcinoma (Grunewald et al, 2007a). The present
continuative long-term follow-up strengthens the assumed
link between increased nuclear LASP-1-localisation and poor
survival of patients with breast cancer suggesting an effect of
nuclear LASP-1 on cell proliferation, especially because the
absolute amount of cytosolic LASP-1-expression does not correlate
with patients’ OS.
Unexpectedly, we found a high nuclear localisation of LASP-1 in
differentiated G1 tumours while in parallel nuclear LASP-1
abundance was correlated with worse prognosis. It is possible
that tumours with a high nuclear LASP-1-expression represent a
subgroup with poor survival irrespective of the grading. This
could, for example, be due to a decreased response to endocrine or
chemotherapeutic treatment. However, the number of available G1
tumours was very low. Therefore, we will not draw definitive
conclusions regarding these data.
On the molecular level, the zinc-finger containing LIM-domain of
LASP-1 offers a possibility for direct binding to DNA (Hammarstrom
et al, 1996). LASP-1 may even form heterodomains to become a
nuclear transcription factor (Kadrmas and Beckerle, 2004).
Although LASP-1 sequence analysis revealed no nuclear
localisation signal, the classical import pathway for the nucleus
(Kutay and Guttinger, 2005), LASP-1 binds to the well-charac-
terised shuttle proteins and transcription factors LPP and Zyxin
that are upregulated in a wide variety of human cancers (Beckerle,
1997; Petit et al, 2003; Keicher et al, 2004; Li et al, 2004; Grunewald
et al, 2009). For Zyxin, it is known that during mitosis a fraction
of the cytoplasmic-dispersed protein becomes phosphorylated
(most likely by Cdc2 kinase) and associates with the tumour
suppressor h-warts (LATS1), a key governor of G2/M-progression,
at the mitotic apparatus (Hirota et al, 2000).
Our data suggest that pathophysiological localisation of LASP-1
in the nucleus of malignant cells may induce mitosis and thereby
enhance cell proliferation, possibly in concert with Zyxin and LPP.
Further work will be needed to identify the nuclear shuttle
partner(s) of LASP-1, the mechanism of nuclear translocation and
the regulation of cell cycle progression.
The present continuative long-term follow-up provides evidence
for the relation of increased nuclear LASP-1-localisation and
poor survival of patients leading to the question whether nuclear
LASP-1-positivity defines a subgroup of patients with unfavour-
able prognosis that is not responding to conventional treatment
approaches. Future work is on the way to elucidate the precise
molecular and clinical effect of LASP-1 nuclear overexpression.
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